Table 1.
First- and second-generation HSP90 inhibitors
| HSP90 inhibitors | Class | Pharmaceutical company |
|---|---|---|
| First-generation HSP90 inhibitors | ||
| Tanespimycin (17-AAG, KOS-953) | Geldanamycin derivative | Kosan Biosciences/Bristol-Myers-Squibb |
| Alvespimycin (17-DMAG) | Geldanamycin derivative | Kosan Biosciences/Bristol-Myers-Squibb |
| Retaspimycin (IPI-504) | Geldanamycin derivative | Infinity Pharmaceuticals |
| IPI-493 | Geldanamycin derivative | Infinity Pharmaceuticals |
| Second-generation HSP90 inhibitors | ||
| CNF2024/BIIB 021 | Purine | Biogen Idec |
| MPC-3100 | Purine | Myriad Pharmaceuticals/Myrexis |
| Debio 0932 (CUDC-305) | Purine-like | DebioPharm |
| PU-H71 | Purine | Samus Therapeutics |
| Ganetespib (STA-9090) | Resorcinol–Triazole | Synta Pharmaceuticals |
| NVP-AUY922 (VER-52269) | Resorcinol–Isoxazole | Novartis |
| NVP-HSP990 | Not reported | Novartis |
| KW-2478 | Resorcinol | Kyowa Hakko Kirin Pharma |
| AT13387 | Resorcinol | Astex |
| SNX-5422 | Indazol-4-one | Serenex/Pfizer |
| DS-2248 | Not reported | Daiichi Sankyo Inc |
| XL888 | Not reported | Exelixis |
Abbreviation: HSP90, heat shock protein 90.